Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 7/20 | 0.66 |
| ▸ | THRA | P10827 | 4/20 | 0.66 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7063021 | 0.99 | THRB (0.67) | THRBTHRAEPHX1EPHX2 | |
| SCHEMBL7062751 | 0.97 | THRB (0.70) | THRBTHRAEPHX1EPHX2 | |
| SCHEMBL7063029 | 0.95 | THRA (0.64) | THRBTHRAEPHX1EPHX2 | |
| SCHEMBL7059647 | 0.95 | THRB (0.75) | THRBTHRA | |
| SCHEMBL7059970 | 0.94 | THRB (0.76) | THRBTHRA | |
| SCHEMBL6660907 | 0.93 | THRB (0.67) | THRBTHRAEPHX1EPHX2 | |
| SCHEMBL7057999 | 0.92 | THRB (0.79) | THRBTHRA | |
| SCHEMBL6658276 | 0.92 | THRA (0.68) | THRBTHRAEPHX1EPHX2 | |
| SCHEMBL7058713 | 0.91 | THRB (0.62) | THRBTHRAEPHX1EPHX2 | |
| SCHEMBL1641848 | 0.91 | THRB (0.68) | THRBTHRAEPHX1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114521-A1 | Oxamic acids and derivatives as thyroid receptor ligands | CHIANG YUAN-CHING PHOEBE (US) | 2003-06-19 | — | — | US | claimed |
| US-6545018-B2 | Treating obesity, hyperlipidemia, glaucoma, arrhythmia, skin disorders, thyroid disease, hypothyroidism, diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression and osteoporosis | PFIZER INC. | 2003-04-08 | — | — | US | claimed |
| US-20020049226-A1 | Oxamic acids and derivatives as thyroid receptor ligands | CHIANG YUAN-CHING PHOEBE (US) | 2002-04-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114521-A1 | Oxamic acids and derivatives as thyroid receptor ligands | OXER1, THRA, TSHR | THRB 4/4885THRA 2/4885EPHX1 648/4885 |
| US-20020049226-A1 | Oxamic acids and derivatives as thyroid receptor ligands | OXER1, THRA, OXGR1 | THRB 4/4885THRA 2/4885EPHX1 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.